Michael Dickinson Haematologist
@drmikedickinson.bsky.social
Haematologist, lymphoma specialist, and Lead of Aggressive Lymphoma at Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Cabrini in Melbourne, Australia. Phase 1 trials, drug development, immunotherapies, CAR-T cell therapy.
Good news for patients with #DLBCL Diffuse large B-cell #lymphoma that #epcoritamab has received a positive funding recommendation from the PBAC in Australia. #lymsm 2L Axi-Cel this week, bispecifics in the 3L soon, it seems. Good news on a Friday. #lymsm
Pharmaceutical Benefits Scheme (PBS) | PBAC Outcomes
See also
buff.ly
December 20, 2024 at 6:42 AM
Good news for patients with #DLBCL Diffuse large B-cell #lymphoma that #epcoritamab has received a positive funding recommendation from the PBAC in Australia. #lymsm 2L Axi-Cel this week, bispecifics in the 3L soon, it seems. Good news on a Friday. #lymsm